X

Trial Profile

SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 12 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Satralizumab (Primary)
Indications Neuromyelitis optica
Focus Registrational; Therapeutic Use
Acronyms SAkuraBONSAI
Sponsors Roche

Most Recent Events

06 Nov 2023 Status changed from recruiting to discontinued because study has proved infeasible to recruit in sufficient numbers. There are insufficient eligible patients presenting to sites.
12 Jul 2023 This trial has been discontinued in Germany.
06 Jul 2023 This trial has been completed in France, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com